TY - JOUR
T1 - Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-γ
AU - Jones, M. S.
AU - Riley, R.
AU - Hamilton, B. L.
AU - Paupe, J.
AU - Perez, D.
AU - Levy, R. B.
N1 - Copyright:
Copyright 2004 Elsevier B.V., All rights reserved.
PY - 1994
Y1 - 1994
N2 - Despite the existence of many non-MHC disparities between MHC matched but non-MHC mismatched donors and recipients, graft-versus-host disease (GVHD) is not clinically apparent following a significant number of allogeneic bone marrow transplants (BMT) in experimental animals. The present studies examined Vβ TcR expression and IFN-γ production by donor T cells in a BMT model involving an MHC matched, allogeneic donor-recipient combination which included a unidirectional superantigen disparity (Mls). B10.D2→BALB/c, but not BALB/c→B10.D2 recipients develop GVHD and mortality ensues 8-12 weeks post-transplant. During the first 2 weeks post-transplant of B10.D2→BALB/c, approximately 50% of all Thy1.2+ spleen and lymph node cells were found to express T cell receptors utilizing Vβ3. A similar rapid and selective expansion of Vβ3+ TcR bearing donor T cells was detected in two other H-2 matched superantigen disparate donor-recipient BMT combinations. An increased percentage of Vβ3+ T cells was noted among both the CD4+ and CD8+ populations. Thus, in these donor/recipient combinations, all TcR families were not equally expanded early following transplant. At 4-10 days post-transplant, IFN-γ specific mRNA was readily detected in the spleens of B10.D2→BALB/cBMT recipients containing large numbers of Vβ3+ T cells. Moreover, Vβ3+ donor T cells from these recipients contained IFN-γ mRNA. Specific stimulation in vitro with immobilized anti-TcR moAbs demonstrated that Vβ3+ T cells secreted a large amount of the total IFN-γ levels detected. The ability of endogenous superantigens to activate large numbers of T cells which can produce cytokines after BMT indicates that when present, such antigenic differences may contribute to events occurring during initial graft-versus-host reactions. Such antigens could therefore participate in the events influencing whether GVHD develops following BMT between certain donors and recipients.
AB - Despite the existence of many non-MHC disparities between MHC matched but non-MHC mismatched donors and recipients, graft-versus-host disease (GVHD) is not clinically apparent following a significant number of allogeneic bone marrow transplants (BMT) in experimental animals. The present studies examined Vβ TcR expression and IFN-γ production by donor T cells in a BMT model involving an MHC matched, allogeneic donor-recipient combination which included a unidirectional superantigen disparity (Mls). B10.D2→BALB/c, but not BALB/c→B10.D2 recipients develop GVHD and mortality ensues 8-12 weeks post-transplant. During the first 2 weeks post-transplant of B10.D2→BALB/c, approximately 50% of all Thy1.2+ spleen and lymph node cells were found to express T cell receptors utilizing Vβ3. A similar rapid and selective expansion of Vβ3+ TcR bearing donor T cells was detected in two other H-2 matched superantigen disparate donor-recipient BMT combinations. An increased percentage of Vβ3+ T cells was noted among both the CD4+ and CD8+ populations. Thus, in these donor/recipient combinations, all TcR families were not equally expanded early following transplant. At 4-10 days post-transplant, IFN-γ specific mRNA was readily detected in the spleens of B10.D2→BALB/cBMT recipients containing large numbers of Vβ3+ T cells. Moreover, Vβ3+ donor T cells from these recipients contained IFN-γ mRNA. Specific stimulation in vitro with immobilized anti-TcR moAbs demonstrated that Vβ3+ T cells secreted a large amount of the total IFN-γ levels detected. The ability of endogenous superantigens to activate large numbers of T cells which can produce cytokines after BMT indicates that when present, such antigenic differences may contribute to events occurring during initial graft-versus-host reactions. Such antigens could therefore participate in the events influencing whether GVHD develops following BMT between certain donors and recipients.
UR - http://www.scopus.com/inward/record.url?scp=0028584254&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028584254&partnerID=8YFLogxK
M3 - Article
C2 - 7889005
AN - SCOPUS:0028584254
VL - 14
SP - 725
EP - 735
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 5
ER -